[The clinical efficacy of epristeride in the treatment of benign prostatic hyperplasia].

Abstract

OBJECTIVES:

To estimate the clinical safety, efficacy of Epristeride in the treatment of benign prostatic hyperplasia (BPH).

METHODS:

One hundred and fourty-one BPH patients, aged from 50 to 83 years old [(66.18 +/- 6.41) yr], were given Epristeride tablets 5 mg p.o., twice daily for 120 days. To synthetically estimate the efficacy by the changing rate of international prostate symptom score (IPSS), maximum flow rate (Qmax), the volume of prostate (V) and the residual urine (Ru).

RESULTS:

The total efficacy was 81.29%. The adverse reactions include 1 case (0.72%) of exanthem, 1 case (0.72%) of nausea and vomiting, 1 case (0.72%) of insomnia, 1 case (0.72%) of tinnitus and 3 cases (2.16%) of erectile dysfunction. Two patients discontinued the treatment due to the side effects (1.44%). There was no clinical significantly abnormal laboratory index during the treatment.

CONCLUSIONS:

Epristeride tablets was safe and effective in the treatment of BPH.

• Authors: Xiao-Bing Ju, Hong-Fei Wu, Li-Xin Hua, Wei Zhang, Jie Li
• Journal: Zhonghua nan ke xue = National journal of andrology (Zhonghua Nan Ke Xue) Vol. 8 Issue 1 Pg. 42-4 ( 2002) ISSN: 1009-3591 [Print] China
• PMID: 12479047 (Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article)

Chemical References

• Androstadienes
• epristeride

Topics

• Aged
• Aged, 80 and over
• Androstadienes (adverse effects, therapeutic use)
• Humans
• Male
• Middle Aged
• Prostatic Hyperplasia (drug therapy)
• Treatment Outcome